

Dr Gertraud Unterrainer Joins ProBioGen as Chief Financial Officer

Berlin (Germany), October 9, 2007 - ProBioGen AG, a leading biotechnology company in mammalian cell engineering and cell culture, today announced the appointment of Dr Gertraud Unterrainer to Chief Financial Officer. Dr Unterrainer will complement and strengthen ProBioGen's current management team consisting of Michael Schlenk, CEO, and Dr Uwe Marx, CSO.

Dr Unterrainer previously served as Chief Financial Officer of Biovertis AG, Vienna and Munich. Prior to that, she was investment manager of an Austrian seed fund and a consultant at McKinsey & Company. Dr Unterrainer has extensive experience in financial management, operations, and capital market relations and has been responsible for numerous financial transactions and M&A activities in the healthcare field.

Michael Schlenk, CEO of ProBioGen AG: "We are very glad about Dr Gertraud Unterrainer's decision to join the management team of ProBioGen. The Company's recent move into profitability is positive proof of its leadership in specialized solutions for mammalian cell engineering and cell culture. Dr Unterrainer's appointment is a good step to complement the current team and to ensure a professional financial management which corresponds with the Company's growing commercial success."

"I am excited to join ProBioGen since the Company has entered into a new phase of corporate development and is committed to expanding its leading market position. My goal is to ensure further growth by establishing a long-term financial strategy and state-of-the-art financial operations, and by strengthening ProBioGen's interactions within the financial and business communities," said Gertraud Unterrainer.

About ProBioGen AG

ProBioGen is a specialist for cell line design, viral vectors, and the manufacture of glycoproteins for the biopharmaceutical industry. The German biotechnology company is headquartered in Berlin. Its range of products and services include the development of highly productive cell lines, the design of novel cell lines from primary tissue, the manufacture of glycoproteins for clinical studies and R&D, as well as the production of viral vectors and antibodies for in vitro diagnostics. ProBioGen possesses the manufacturing authorization for pharmaceutically usable active substances for testing in clinical studies and meets the quality standards recommended by the EU (EMA) and the FDA. A certified cGMP multipurpose facility is available for contract production of biopharmaceutical active substances. The Company is specialized in mammalian cells and combines the know-how of molecular biology scientists with the experience of experts in cell culture technology and process engineering. ProBioGen thus accompanies its clients from the early development of product candidates up to late clinical testing phase.

ProBioGen Contact

Michael Schlenk
Goethestraße 54
13086 Berlin
Tel.: +49 (30) 924-006-0
Fax: +49 (30) 924-006-19
e-mail: michael.schlenk@probiogen.de